Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Director Daniel G. Welch sold 217 shares of Intercept Pharmaceuticals stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the sale, the director now directly owns 3,710 shares of the company’s stock, valued at $470,279.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Intercept Pharmaceuticals, Inc. (ICPT) opened at 127.40 on Friday. The company has a 50-day moving average price of $123.24 and a 200 day moving average price of $117.13. The firm’s market cap is $3.19 billion. Intercept Pharmaceuticals, Inc. has a 12 month low of $96.63 and a 12 month high of $177.93.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The firm had revenue of $21 million for the quarter, compared to analysts’ expectations of $15.88 million. During the same quarter last year, the company posted ($5.17) earnings per share. Intercept Pharmaceuticals’s revenue was up 4566.7% on a year-over-year basis. Equities research analysts anticipate that Intercept Pharmaceuticals, Inc. will post ($14.40) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/22/daniel-g-welch-sells-217-shares-of-intercept-pharmaceuticals-inc-nasdaqicpt-stock.html.

Institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 0.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 14 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares in the last quarter. Oppenheimer & Co. Inc. boosted its position in shares of Intercept Pharmaceuticals by 9.0% in the first quarter. Oppenheimer & Co. Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 178 shares in the last quarter. Pacer Advisors Inc. boosted its position in shares of Intercept Pharmaceuticals by 21.6% in the first quarter. Pacer Advisors Inc. now owns 1,861 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 330 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Intercept Pharmaceuticals by 3.0% in the first quarter. Teachers Advisors LLC now owns 15,871 shares of the biopharmaceutical company’s stock worth $1,795,000 after buying an additional 461 shares in the last quarter. 84.25% of the stock is currently owned by hedge funds and other institutional investors.

ICPT has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $60.00 price target on Intercept Pharmaceuticals and gave the stock a “sell” rating in a report on Thursday, May 4th. Laidlaw raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 price target for the company in a report on Friday, May 5th. Wedbush reaffirmed an “outperform” rating and set a $231.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, May 26th. Cowen and Company reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Monday, June 12th. Finally, ValuEngine raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Three analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $195.75.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.